# A Phase II Multi-centre, Extension Study to Investigate the Long Term Safety of ONO-2506PO in Patients Diagnosed With Amyotrophic Lateral Sclerosis (ALS)

> **NCT00694941** · PHASE2 · COMPLETED · sponsor: **Ono Pharmaceutical Co., Ltd.** · enrollment: 15 (actual)

## Conditions studied

- Amyotrophic Lateral Sclerosis (ALS)

## Interventions

- **DRUG:** ONO-2506PO

## Key facts

- **NCT ID:** NCT00694941
- **Lead sponsor:** Ono Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-06
- **Primary completion:** 2008-12
- **Final completion:** —
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2012-06-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00694941

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00694941, "A Phase II Multi-centre, Extension Study to Investigate the Long Term Safety of ONO-2506PO in Patients Diagnosed With Amyotrophic Lateral Sclerosis (ALS)". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT00694941. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*